These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33272166)

  • 41. Bioactive-Chylomicrons for Oral Lymphatic Targeting of Berberine Chloride: Novel Flow-Blockage Assay in Tissue-Based and Caco-2 Cell Line Models.
    Elsheikh MA; Elnaggar YSR; Otify DY; Abdallah OY
    Pharm Res; 2018 Jan; 35(1):18. PubMed ID: 29305670
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lymphatic Delivery of Anti-HIV Drug Nanoparticles.
    Nayak Y; Avadhani K; Mutalik S; Nayak UY
    Recent Pat Nanotechnol; 2016; 10(2):116-27. PubMed ID: 27502389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor.
    Hauss DJ; Fogal SE; Ficorilli JV; Price CA; Roy T; Jayaraj AA; Keirns JJ
    J Pharm Sci; 1998 Feb; 87(2):164-9. PubMed ID: 9519148
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipid-Based Oral Formulation Strategies for Lipophilic Drugs.
    Patel V; Lalani R; Bardoliwala D; Ghosh S; Misra A
    AAPS PharmSciTech; 2018 Nov; 19(8):3609-3630. PubMed ID: 30255474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability.
    Kohli K; Chopra S; Dhar D; Arora S; Khar RK
    Drug Discov Today; 2010 Nov; 15(21-22):958-65. PubMed ID: 20727418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Solid Lipid Nanoparticles Approach for Lymphatic Targeting Through Intraduodenal Delivery of Quetiapine Fumarate.
    Yasir M; Gaur PK; Puri D; Shehkar P; Kumar SS
    Curr Drug Deliv; 2018; 15(6):818-828. PubMed ID: 28545354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lymphatic transport of orally administered drugs.
    Reddy LH; Murthy RS
    Indian J Exp Biol; 2002 Oct; 40(10):1097-109. PubMed ID: 12693689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.
    Trevaskis NL; Kaminskas LM; Porter CJ
    Nat Rev Drug Discov; 2015 Nov; 14(11):781-803. PubMed ID: 26471369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strategies and industrial perspectives to improve oral absorption of biological macromolecules.
    Liu C; Kou Y; Zhang X; Cheng H; Chen X; Mao S
    Expert Opin Drug Deliv; 2018 Mar; 15(3):223-233. PubMed ID: 29111841
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular targeting of liposomal nano-particles to lymphatic system.
    Cuong NV; Hsieh MF
    Curr Cancer Drug Targets; 2011 Feb; 11(2):147-55. PubMed ID: 21158721
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU.
    White KL; Nguyen G; Charman WN; Edwards GA; Faassen WA; Porter CJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):700-9. PubMed ID: 19696095
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential of Liposomes for Enhancement of Oral Drug Absorption.
    Daeihamed M; Dadashzadeh S; Haeri A; Akhlaghi MF
    Curr Drug Deliv; 2017; 14(2):289-303. PubMed ID: 26768542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nano-based drug delivery system enhances the oral absorption of lipophilic drugs with extensive presystemic metabolism.
    Zhang Z; Gao F; Jiang S; Ma L; Li Y
    Curr Drug Metab; 2012 Oct; 13(8):1110-8. PubMed ID: 22380010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ligand-mediated active targeting for enhanced oral absorption.
    Zhang X; Wu W
    Drug Discov Today; 2014 Jul; 19(7):898-904. PubMed ID: 24631680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Key Considerations in Designing Oral Drug Delivery Systems for Dogs.
    Song Y; Peressin K; Wong PY; Page SW; Garg S
    J Pharm Sci; 2016 May; 105(5):1576-1585. PubMed ID: 27056627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Challenges in the prediction and modeling of oral absorption and bioavailability.
    Metcalfe PD; Thomas S
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):104-10. PubMed ID: 20047151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats.
    Caliph SM; Charman WN; Porter CJ
    J Pharm Sci; 2000 Aug; 89(8):1073-84. PubMed ID: 10906731
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mucoadhesive in situ nasal gelling drug delivery systems for modulated drug delivery.
    Singh RM; Kumar A; Pathak K
    Expert Opin Drug Deliv; 2013 Jan; 10(1):115-30. PubMed ID: 23199072
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development and
    Xu Q; Zhou A; Wu H; Bi Y
    Pharm Dev Technol; 2019 Nov; 24(9):1155-1163. PubMed ID: 31342830
    [No Abstract]   [Full Text] [Related]  

  • 60. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.
    Han S; Quach T; Hu L; Wahab A; Charman WN; Stella VJ; Trevaskis NL; Simpson JS; Porter CJ
    J Control Release; 2014 Mar; 177():1-10. PubMed ID: 24398334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.